Assessment of HER2 status in breast cancer: Why, when and how?

European Journal of Cancer

Volumn 36, Issue 2, 2000, Pages 170-176

  Dowsett, M ^a,g   Cooke, T ^b,d   Ellis, I ^c,e   Gullick, W J ^b,f   Mallon, E ^a,e,g   Walker, R ^d,f  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f WESTERN INFIRMARY   (United Kingdom)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Breast cancer; HER2; Pathology; Tumour markers

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG RESISTANCE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

EID: 0033965962     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00264-6     Document Type: Article

References (62)

1. Riese DJ, Stern DF. Specificity within the EGF family/erbB receptor family signalling network. Bioessays 1998, 20, 41-48.
2. van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Ann Rev Cell Blol 1994, 10,251-337.
3. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEES Lett 1997, 410, 83-86.
4. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16, 1647-1655.
5. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996, 15, 254-264.
6. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16, 5276-5287.
7. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992, 24, 85-95.
8. Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor. Oncogene 1992, 7, 1859-1866.
9. HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sei USA 1987,84, 7159-7163.
10. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Ada Rev Cancer 1994, 1198, 165-184.
11. Slamon D, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989,244, 707-712.
12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987,235, 177-182.
13. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14, 737-744.
14. Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Monoclonal antibodies directed to the ereB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 1993, 68, 1140-1145.
15. Sias PE, Kotts CE, Vetterlein D, Shepard M, Wong WL. ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods 1990, 132, 73-80.
16. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998, 16, 413-428.
17. Pawlowski V, Révillion R, Hornez L, Peyrat JP. Low concentrations of c-erbB-2 mRNA (real time RT-PCR) are associated with a poor prognosis in 404 unselected primary human breast cancers. Proc Am Assoc Cancer Res 1999, 40, 204.
18. Reeves JR, Going JJ, Smith G, Cooke TG, Ozanne BW, Stanton PD. Quantitative radioimmunohistochemical measurements of p!85 (erbB-2) in frozen tissue sections. J Histochem Cytochem 1996,44, 1251-1259.
19. Robertson KW, Reeves JR, Smith G, et al. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 1996, 56, 3823-3830.
20. Chong D, Reeves JR, Cooke TG, et al. Quantitation of c-erbB-2 in primary breast cancer: gene amplification is not the whole picture. Br J Cancer 1998, 78(Suppl. 2), 24.
21. Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR. Overexpression of the c-ereB-2 oncogene: why does this occur more frequently in ductal carcinoma In situ than in invasive mammary carcinoma and is this of prognostic significance. Eur J Cancer 1992, 28A, 644-648.
22. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma and limited prognostic value in Stage II breast cancer. N Engl J Med 1988, 319, 1239-1245.
23. Piccart MJ, Awada A, Hamilton A. Integration of new therapies into management of metastatic breast cancer: a focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. In Perry MC, ed. American Society of Clinical Oncology educational book. Alexandria, VA, American Society of Clinical Oncology, 1999, 536-539.
24. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995, 10, 2435-2446.
25. Berns EMJJ, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995, 159, 11-18.
26. Bianco AR, De Laurentis M, Carlomagno C, et al. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-ere-B2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 1998, 17, 97A.
27. Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995, 13, 1129-1135.
28. Newby JC, Johnston SRD, Smith IE, Dowsett M. Expression of epidermal growth factor receptor and c-erb B2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997, 3, 1643-1651.
29. Nicholson RI, McClelland RA, Finlay P, et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993, 29A, 1018-1023.
30. Plunkett TA, Houston SJ, Rubens RD, Miles DW. c-erbB2 is a marker of resistance to endocrine therapy in advanced breast cancer. Proc Am Soc Clin Oncol 1998, 17, 103a.
31. Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992, 65, 118-121.
32. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997, 15, 2518-2525.
33. Archer SG, Eliopoulos SA, Spandidos D, et al. Expression of ras p21, p53 and C-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995, 72, 1259-1266.
34. Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998, 4, 7-12.
35. Muss H, Berry D, Thor A, et al. Lack of interaction of tamoxifen (T) use and ErbB-2/HER-2/neu (H) expression in CALGB 8541: a randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAP) in node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 1999,18, 68a.
36. Allred DC, Clark GM, Tandon AK, et al. HEK.-2/neu in nodenegative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992, 10, 599-605.
37. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismondi P. Prognostic and predictive relevance of c-ereB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994, 14, 1441-1450.
38. Gusterson BA, Gelber RD, Goldhirsch KN, et al. Prognostic importance of c-ereB-2 expression in breast cancer. J Clin Oncol 1992, 10, 1049-1056.
39. Stâl O, Sullivan S, Wingren S, et al. c-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995, 31A, 2185-2190.
40. Ménard S, Valagussa S, Pilotti E, et al. Benefit of CMF treatment in lymph-node positive breast cancer overexpressing HER2. Proc Am Soc Clin Oncol 1999, 18, 69a.
41. Miles DW, Harris WH, Gillett CE, Smith P, Barnes DM. Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 1999,84, 354-359.
42. Muss HB, Thor AD, Berry DA, et al. c-erbR-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994, 330, 1260-1266.
43. Budman DR, Berry DA, Cirrincione CT, et al. Dose and doseintensity as determinants of outcome in the adjuvant treatment of breast cancer: the Cancer and Leukemia Group B. J Nat! Cancer Ins t 1998,90, 1205-1211.
44. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Nail Cancer Inst 1998, 90, 1346-1360.
45. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Nat! Cancer Inst 1998, 90, 1361-1370.
46. Ravdin PM, Green S, Albain V, et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAP T with tamoxifen (T) alone. Proc Am Soc Clin Oncol 1998, 17, 97a.
47. Clahsen PC, van de Velde CJ, Duval C, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998, 16, 470-479.
48. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius V-M. Predictive value of c-ereB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 1997,76,917-922.
49. Rozan S, Vincent-Salomon A, Zafrani B, et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998, 79, 27-33.
50. Untch M, Thomssen C, Kahlert D, et al. Lack of c-erbB-2 overexpression predicts better response to dose intensification of anthracycline-based chemotherapy in high-risk breast cancer. Abstract no. 110 presented at the San Antonio Breast Cancer Conference, 12-15 Dec. 1998.
51. Busmanis I, Feleppa F, Jones A, et al. Analysis of c-ereB2 expression using a panel of 6 commercially available antibodies. Pathology 1994, 26, 261-267.
52. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER.-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994, 54, 2771-2777.
53. Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 1994, 173, 65-75.
54. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996, 88, 1054-1059.
55. Farabegoli F, Ceccarelli C, Santini D, et al. c-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples. Int J Cancer 1999, 84, 273-277.
56. Espinoza F, Anguiano A. The HercepTest assay: another perspective. J Clin Oncol 1999, 17, 2293-2294.
57. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999, 17, 1983-1987.
58. Maia DM. Immunohistochemical assays for HER2 overexpression. Clin Oncol 1999, 17, 1650.
59. Roche PC, Ingle JN. Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 1999, 17, 434.
60. Hynes NE, Gerber HA, Saurer S, Groner B. Overexpression of the c-ereB-2 protein in human breast tumor cell lines. J Cell Biochem 1989,39, 167-173.
61. Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987, 6, 605-610.
62. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996, 13, 63-72.